XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
Share
Why It Matters
XORTX is moving forward with testing a new gout medicine in Canada. When companies take steps forward on new drugs, investors watch to see if the medicine works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.